Clinical Trials Directory

Trials / Completed

CompletedNCT01748630

Effects of Dexmedetomidine on the Postoperative Experience in Children

Pain, Fentanyl Consumption, and Delirium in Children After Scoliosis Surgery: Dexmedetomidine Versus Midazolam

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
42 (actual)
Sponsor
Inonu University · Academic / Other
Sex
All
Age
12 Years – 18 Years
Healthy volunteers
Accepted

Summary

Background: The study aim was to compare the efficacy of dexmedetomidine versus midazolam for sedation during the early postoperative period in children who underwent scoliosis surgery. Methods: We performed a prospective, randomized trial in an intensive care unit (ICU) in a tertiary care center. In this study, 42 patients (American Society of Anesthesiology physical status I and II) who underwent scoliosis surgery were divided into 2 groups according to sedation protocols: group DEX (n = 22) and group MDZ (n = 20). Children (12-18 years) requiring mechanical ventilation underwent a continuous infusion of either dexmedetomidine (group DEX; starting dose, 0.4 μg•kg-1•h-1) or midazolam (group MDZ; starting dose, 0.1 mg•kg-1•h-1) with intermittent fentanyl, as needed. The efficacy of sedation was assessed using the Richmond Agitation Sedation Scale (RASS). Quality of pain relief was measured using the Numeric Visual Analog Scale (NVAS). During the arousal assessment, delirium was determined in patients in the RASS range of -2 to +1 using the Confusion Assessment Method for the ICU (CAM-ICU). Fentanyl consumption, incidence of delirium, NVAS scores, and hemodynamics were recorded postoperatively at 2, 4, 6, and 24 h in the ICU.

Conditions

Interventions

TypeNameDescription
DRUGdexmedetomidine
DRUGMidazolam
DRUGfentanyl

Timeline

Start date
2012-02-01
Primary completion
2012-09-01
Completion
2012-10-01
First posted
2012-12-12
Last updated
2012-12-12

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT01748630. Inclusion in this directory is not an endorsement.